Business
New Nuvec® opportunity and patent filing
New Nuvec® opportunity and patent filing.
About this update from Thalia Therapeutics Plc
[{"type":"text","content":"\n \n \n RNS Number : 7167K\n N4 Pharma PLC\n 24 April 2020\n \n \n \n \n 24 April \n 2020\n \n \n N4 Pharma Plc\n \n \n (\"N4 Pharma\" or the \"Company\")\n \n \n \n \n \n New Nuvec® opportunity and patent filing\n \n \n \n \n \n N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, announces that it \n has filed a new UK patent application around both Nuvec®'s ability to be used to manufacture viral vectors and to make viral vectors more efficient in applications such as ex-vivo gene therapy treatments.\n \n \n \n \n \n Nuvec® has a unique structure that allows the easy loading of DNA plasmids. The manufacture of viral vectors typically requires the use of two or more plasmids. Nuvec® has been shown to be capable of loading multiple plasmids. In recent research conducted by the Company, it has been demonstrated that loading Nuvec® with the three plasmids typically used to produce lentivirus, resulted in an increase in the amount of the desired viral vector produced. The manufacture of viral vectors is an expensive process, so utilising Nuvec®'s ability to efficiently load and deliver multiple plasmids could greatly reduce the cost involved in this process.\n \n \n An important use of viral vectors is in ex-vivo gene therapy. In this approach, a patient's cells are taken from their body and more are grown in the laboratory. Whilst still outside the body, these cells are modified by adding the gene of interest into the cells' DNA by using viral vectors that are carrying the gene. These cells, carrying the gene designed to treat the patient, are then re-inserted back into the patient's body. In separate research, the Company has demonstrated that when complexed with a lentivirus carrying a gene of interest, Nuvec® can be used as a reagent to produce cells containing the gene using a fraction of the original lentivirus, thereby suggesting that this process can be made cheaper and more efficient.\n \n \n The Company is now working with external consultants to identify how best to enter the virus manufacture and ex-vivo gene therapy markets\n .\n \n \n \n \n \n \n \n \n Nigel Theobald, Chief Executive Officer of the Company, commented:\n \n \n \n \n \n \"Whilst investigating the dispersion of Nuvec...